Las Vegas, NV -- (SBWIRE) -- 12/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Genco Shipping & Trading Limited (NYSE:GNK), Idera Pharmaceuticals Inc (NASDAQ:IDRA), Zalicus Inc (NASDAQ:ZLCS), North American Palladium Ltd (USA) (NYSEMKT:PAL)
Genco Shipping & Trading Limited (NYSE:GNK) managed to keep its gain at 10.70% on above-normal volume of 1.97M shares. The stock settled at $2.69 after floating in a range of $2.43 to $2.69. Its latest price has reached market capitalization of $119.57 million. Its 52-week range has been $1.12 to $4.98. Genco Shipping & Trading Limited (GS&T) transports iron ore, coal, grain, steel products and other drybulk cargoes along worldwide shipping routes through the ownership and operation of drybulk carrier vessels. As of December 31, 2012, GS&T’s fleet consisted of 53 drybulk carriers, including nine capesize, eight panamax, 17 supramax, six handymax and 13 handysize drybulk carriers, with an aggregate carrying capacity of approximately 3,810,000 deadweight tonnages.
For How Long GNK will fight for Profitability? Read This Trend Analysis report
Idera Pharmaceuticals Inc (NASDAQ:IDRA) traded up on a volume of 1.95 million, higher than its standard daily volume. Shares have gained 21.89% to $2.45. Over the last twelve months, the stock has gained 8.89% and faced a worst price of $0.19. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA.
For How Long IDRA’s Gloss will Attract Investors? Find out via this report
Zalicus Inc (NASDAQ:ZLCS) settled 6.14% higher at $1.21 on below -normal volume of 1.90M shares during the last trading day. The stock has its 12-month high at $8.28 and 52-week low price was $0.88. It traded in a range of $1.10 to $1.24 during the last trading day. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.
Why Should Investors Buy ZLCS After the Recent Fall? Just Go Here and Find Out
In the last trading session, North American Palladium Ltd (USA) (NYSEMKT:PAL) was down on low volume, trading at a volume of 1.86M versus its average daily volume of 1.97 million shares. At $0.426, the stock has attained market capitalization of 83.85 million. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. The Company’s 100%-owned subsidiary is the Lac des Iles Mines Ltd. (LDI).
Why Should Investors Buy PAL After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment A
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)